In a new systematic review, Chr. Hansen scientists have compiled data from 26 clinical studies on HMOs, concluding there is a wealth of evidence that these are well-tolerated modulators of the gut microbiome providing health benefits.
Individual human milk oligosaccharides (HMOs) may play critical roles in the maturation of gray matter in an infant brain, showing that inclusion of specific HMOs in infant formula could be beneficial, says a new study.
Chr. Hansen has received regulatory approval to supply a range of Human Milk Oligosaccharides (HMO) to new and existing global markets, following recent endorsements from Australia and New Zealand last year.
Levels of two specific human milk oligosaccharides (HMOs) are linked with measure of infant cognitive development, says a pilot study led by R&D Abbott Nutrition.